103 results
8-K
PCSA
Processa Pharmaceuticals Inc
11 Apr 24
Regulation FD Disclosure
8:00am
significantly increases 5-FU exposure while improving safety profile compared to capecitabine, April 8, 2024.
Application of Phase 1 and pre-clinical data
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
6 Feb 24
Other Events
8:30am
generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it has received notice from … Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces the pricing of a public offering … company focused on developing the Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. By combining
424B4
r91wnbmw1eexh67rl
29 Jan 24
Prospectus supplement with pricing info
4:15pm
8-K
6t4p91mnv
25 Jan 24
NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine
8:35am
8-K
EX-99.1
famyypz4bq
25 Jan 24
NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine
8:35am
8-K
EX-99.1
aqq05wt6 47e
19 Jan 24
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
8:00am
8-K
EX-99.1
yf3w4gkyn2751p
18 Jan 24
Material Modifications to Rights of Security Holders
8:30am
8-K
6w26vfwen5e7
19 Dec 23
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU
9:00am
8-K
EX-99.1
rm58c2
19 Dec 23
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU
9:00am
8-K
EX-99.1
2p14timpkvub3ou6se
13 Nov 23
Departure of Directors or Certain Officers
2:45pm
8-K
EX-3.1
m2cu 9233gq2db
21 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:29pm
8-K
EX-99.1
j6qtf9 grtxg1hq4vhzz
8 Aug 23
Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer
10:30am